Terminology Challenges: Defining Modified Release Dosage Forms in Veterinary Medicine

Martinez, Marilyn N.; Lindquist, Danielle; Modrić, Sanja

doi:10.1002/jps.22095

Cited by 7 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over many years, industry has made great strides in developing new modalities of AMD administration and new formulations. Terminologies describing dosage forms and release characteristics can be confusing; they have has been reviewed in a veterinary context (Martinez, Lindquist, & Modric, 2010).…”

Section: Rational Uses Of Antimicrobial Drugs In Veterinary Medicinementioning

confidence: 99%

A history of antimicrobial drugs in animals: Evolution and revolution

Lees

Pelligand

Giraud

et al. 2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The evolutionary process of antimicrobial drug (AMD) uses in animals over a mere eight decades (1940–2020) has led to a revolutionary outcome, and both evolution and revolution are ongoing, with reports on a range of uses, misuses and abuses escalating logarithmically. As well as veterinary therapeutic perspectives (efficacy, safety, host toxicity, residues, selection of drug, determination of dose and measurement of outcome in treating animal diseases), there are also broader, nontherapeutic uses, some of which have been abandoned, whilst others hopefully will soon be discontinued, at least in more developed countries. Although AMD uses for treatment of animal diseases will continue, it must: (a) be sustainable within the One Health paradigm; and (b) devolve into more prudent, rationally based therapeutic uses. As this review on AMDs is published in a Journal of Pharmacology and Therapeutics, its scope has been made broader than most recent reviews in this field. Many reviews have focused on negative aspects of AMD actions and uses, especially on the question of antimicrobial resistance. This review recognizes these concerns but also emphasizes the many positive aspects deriving from the use of AMDs, including the major research‐based advances underlying both the prudent and rational use of AMDs. It is structured in seven sections: (1) Introduction; (2) Sulfonamide history; (3) Nontherapeutic and empirical uses of AMDs (roles of agronomists and veterinarians); (4) Rational uses of AMDs (roles of pharmacologists, clinicians, industry and regulatory controls); (5) Prudent use (residue monitoring, antimicrobial resistance); (6) International and inter‐disciplinary actions; and (7) Conclusions.

show abstract

Section: Rational Uses Of Antimicrobial Drugs In Veterinary Medicinementioning

confidence: 99%

A history of antimicrobial drugs in animals: Evolution and revolution

Lees

Pelligand

Giraud

et al. 2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Ivermectin (IVM), an antiparasitic macrolide, is widely used in cattle, sheep, pigs, and other animals. Long-acting or sustained-release formulations of IVM have been authorized for its use in animals in several countries ( Martinez, Lindquist & Modric, 2010 ). IVM can be incorporated into a soluble silicate glass ingredient to form a sustained-release bolus.…”

Section: Introductionmentioning

confidence: 99%

Preparation and in vitro release kinetics of ivermectin sustained-release bolus optimized by response surface methodology

Ruan

Gao

et al. 2018

PeerJ

View full text Add to dashboard Cite

Sustained-release formulations of ivermectin (IVM) are useful for controlling parasitic diseases in animals. In this work, an IVM bolus made from microcrystalline cellulose (MCC), starch and low-substituted hydroxypropyl cellulose (LS-HPC) was optimized by response surface methodology. The bolus was dissolved in a cup containing 900 mL of dissolution medium at 39.5 °C, under with stirring at 100 rpm. A quadratic model was formulated using analysis of variance according to the dissolution time. The optimized formulation of the bolus contained 8% MCC, 0.5% starch, and 0.25% LS-HPC. The length, width, and height of the prepared IVM bolus were 28.12 ± 0.14, 16.1 ± 0.13, and 13.03 ± 0.05 mm, respectively. The bolus weighed 11.4842 ± 0.1675 g (with a density of 1.95 g/cm3) and contained 458.26 ± 6.68 mg of IVM. It exhibited in vitro sustained-release for over 60 days, with a cumulative amount and percentage of released IVM of 423.72 ± 5.48 mg and 92.52 ± 1.20%, respectively. The Korsmeyer–Peppas model provided the best fit to the dissolution release kinetics, exhibiting an R2 value close to 1 and the lowest Akaike Information Criterion among different models. The parameter n (0.5180) of the Korsmeyer–Peppas model was between 0.45 and 0.89. It was demonstrated that the release mechanism of the IVM bolus followed a diffusive erosion style.

show abstract

Final Product Testing and the Development of Specifications for Veterinary Pharmaceuticals

Brumfield

2012

Advances in Delivery Science and Technology

View full text Add to dashboard Cite

Terminology Challenges: Defining Modified Release Dosage Forms in Veterinary Medicine

Cited by 7 publications

References 21 publications

A history of antimicrobial drugs in animals: Evolution and revolution

A history of antimicrobial drugs in animals: Evolution and revolution

Preparation and in vitro release kinetics of ivermectin sustained-release bolus optimized by response surface methodology

Final Product Testing and the Development of Specifications for Veterinary Pharmaceuticals

Contact Info

Product

Resources

About